Intellipharmaceutics International Inc. (IPCI): Cysonic, Interesting thought that IPCI w...

Cysonic, Interesting thought that IPCI would want Purdue

Samsa · 2019-01-25T12:27:50.7770000Z

Cysonic, Interesting thought that IPCI would want Purdue Pharma tech added. I am not sure why. If Purdue themselves did not feel they had any claim over the original patents, why would IPCI ? If Purdue felt they had any claim over the patents they would have tried to add them in the first place. I will admit without having first hand knowledge I can't be sure one way or the other. So you could be right. The reason I said this is bad is because the case was set for trial, until IPCI requested the stay. by adding another plaintiff this late it allows for numerous delays. because now the new Plaintiff would be afforded the same discovery and options to depose witnesses. In theory it could stall the case for another year.

Play Episode

5min

Proactive - Interviews for investors

Element 25 delivers positive Tokyo Bay Scoping Study

Element 25 managing director Justin Brown talked with Proactive about the recent completion of the Tokyo Bay HPMSM Facility Scoping Study in partnership with Nissin Chemical Corporation. The company said the results of the scoping study were positive enough to justify advancing the project to the pre-feasibility stage. Brown explained that the Tokyo Bay site offers unique advantages, including a co-located sulfuric acid plant, deepwater port access, and supporting infrastructure critical for high-purity manganese sulfate production. “We took our learnings from the detailed work we’ve done in Louisiana… and converted them to a Japanese setting,” Brown said. He also noted that Japan's regulatory and geopolitical environment makes it an ideal location for refining and supplying the local battery market. Looking ahead, Brown confirmed that Element 25 and Nissin Chemical will conduct deeper engineering and cost analysis under their existing MOU, with a final investment decision targeted for June 2026. The next milestone will be the pre-feasibility study, expected later this year. Brown also discussed how the Tokyo Bay project fits into the company’s broader “design one, build many” strategy, which aims to establish a global network of refineries fed by ethically sourced manganese from Element 25’s Butcherbird mine. In addition to activity in Japan, Brown highlighted ongoing work in Europe and updates on the Butcherbird expansion and Louisiana project, with construction planned to commence later this year. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #Element25 #Manganese #BatteryMetals #TokyoBay #CriticalMinerals #EVSupplyChain #HPMSM #ButcherbirdProject #CleanEnergyMaterials #JapanRefinery #MiningNews #GreenMetals #ProactiveInvestors

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Zinnwald Lithium wins Saxony government endorsement for lithium project after robust PFS

Zinnwald Lithium PLC (LSE:ZNWD, OTC:ZNWLF) chief executive Anton du Plessis talked with Proactive's Stephen Gunnion about the company’s recently published pre-feasibility study (PFS) for its Zinnwald Lithium Project, located in Saxony, Germany. The project is designed to supply battery-grade lithium hydroxide to the European market and has now received public backing from the Saxony government. Du Plessis outlined that the PFS demonstrates a scalable, long-life mining operation, starting with 18,000 tonnes per annum of lithium hydroxide and potentially scaling to 35,000 tonnes in a second phase. He stated, “We published our PFS on Monday that showed an economic project of significant scale… a globally significant project in terms of scale.” The economics were highlighted as robust, with a post-tax NPV of €2.20 billion and an internal rate of return of approximately 20%. The location of the project — 35km south of Dresden — positions it strategically at the heart of Germany and the EU, aligning with Europe’s push for regional supply chains of critical raw materials. Du Plessis also emphasised the importance of the local endorsement, noting, “To have the public endorsement, as we had, is extremely important to us.” The next step for the company is to optimise the project in preparation for a Definitive Feasibility Study, expected in 2026. Visit Proactive's YouTube channel for more interviews like this. Don't forget to like this video, subscribe to the channel, and hit the notification bell to stay updated on future content. #Lithium #BatteryMetals #ZinnwaldLithium #GermanMining #Saxony #CriticalMinerals #EVsupplychain #LithiumHydroxide #EUrawmaterials #MiningInvestment #PFS #CleanEnergy #ZinnwaldProject

Followers	8
Posts	1427
Boards Moderated	0
Alias Born	06/30/2016

Volume:	-
Day Range:
Bid:	0.07
Ask:	0.12
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

IPCI Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free